For the Covid vaccine of Modern 93 efficacy that lasts for 6 months after the second dose. This is the figure that emerges from the final analysis of the results of the Phase 3 Cove study, communicated by the American company as part of the presentation of company updates and financial results for the second quarter of 2021.
A chapter is also dedicated to variants and the company also explained that “robust antibody responses” against important coronavirus variants of concern, including Delta, have been observed for the 3 vaccine candidates currently in phase 2 of the trial by Moderna. . In a phase 2 study, Moderna reports, vaccination with 50 micrograms of 3 different ‘booster’ candidates was evaluated. Strong antibody responses were observed against both the D614G strain of the pandemic coronavirus, as well as the major variants of concern, including Brazilian Gamma (P.1), South African Beta (B.1.351), and Indian Delta (B .1.617.2). Booster candidates included both a booster dose of the current vaccine and the two investigational products mRna-1273.351 and mRna-1273.211. Neutralizing antibody levels after booster approached those seen after primary vaccination with 2 doses of 100 micrograms mRna-1273, i.e. the current Moderna vaccine. This data has been submitted to a peer-reviewed journal for publication, the company points out.
Moderna has received emergency authorization for the use of its vaccine in adults from regulatory bodies in more than 50 countries and the emergency use list from the World Health Organization (WHO), as well as the green light for its use. in adolescents aged 12 and over, in the EU and Japan. On June 1, the company began the process to obtain full and definitive authorization for the vaccine in the US (Bla, Biologics License Application) and expects to complete the submission process by August. Meanwhile, Moderna is also working with other regulatory bodies to authorize or approve the product in other jurisdictions.
Meanwhile, the company has completed enrollment and a phase 1 study is underway for a next-generation Covid vaccine (mRna-1283) potentially stable in the refrigerator, a quality that could facilitate distribution and storage. In this next-generation vaccine candidate (which encodes portions of the Sars-CoV-2 Spike protein crucial for neutralization, particularly Rbd and Ntd), the encoded antigen is shorter than that of the current mRna- 1273. Its characteristics could facilitate the ‘logistics’ of this product and also its administration by healthcare professionals, explains the company.
“I am proud of the progress of our teams”, commented Stéphane Bancel, CEO of Moderna. “We now have mRna candidates in clinical trials in 5 therapeutic areas, including infectious diseases, cardiovascular, oncology, rare diseases and autoimmune diseases. We are delighted that our Covid vaccine shows 93% lasting efficacy for 6 months, but we recognize that the Delta variant is a significant new threat, so we must remain vigilant. ”
Looking ahead, Bancel adds: “We have started preparing late stage studies for our influenza vaccine and for respiratory syncytial virus (RSV) vaccine, which received rapid designation from the FDA a few days ago, and we look forward to ours. vision of a single annual booster dose that provides protection against Covid, flu and RSV for adults. We believe this is just the beginning. “